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Abstract 
 
Cancer therapeutic agents such as IL-2, IL-12 and TRAIL have been shown to have 
promising results in treating various tumor types including glioma and melanoma. The 
challenge remains in the delivery of the agents locally in a controllable manner. 
Mesenchymal stem cells (MSCs) have emerged in the forefront of such applications. 
Recent developments in research have clearly demonstrated the affinity of the MSCs 
towards tumors and the possibility of engineering MSCs, using viral and non-viral 
vectors. Many studies made in the past decades focus on viral vectors due to their 
relatively high efficiency. However, more researchers are currently trying to modify 
non-viral vectors and increase their efficiency to have a safer and more effective 
method for gene delivery to MSCs. Nevertheless, the non-viral vectors studied to 
transfect MSCs are considered not effective enough and some also have cytotoxicity 
risks associated with them. In this study we first review the safety and efficiency of non-
viral vectors used to genetically engineer MSCs for cancer therapy along with their 
application in cancer therapy. We synthesized and tested calcium alginate nanoparticles 
for gene delivery to mesenchymal stem cells. The size, morphology, transfection 
efficiency, and safety of the nanoparticles were studied using various qualification and 
quantification methods. 
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Chapter 1   Introduction 
 
1.1 Cancer therapy 
 
American cancer society has estimated about 1,685,210 new cases of cancer diagnosis 
in the United States in 2016. Figure 1.1 shows a state-based statistical scheme of their 
estimation [1]. Based on their prediction, about 595,690 of these cases are going to be 
terminal [1]. What can be contemplated from these statistical estimation is the question 
of how effective our current treatment methods are and if we need to look for new 
approaches to deal with the situation before it turns into a crisis. The conventional 
Figure 1.1 Estimated numbers of new cancer diagnosis in 2016 in different states of the United States 
based on American cancer society. “American Cancer Society.  Cancer Facts and Figures 2016.  Atlanta: 
American Cancer Society, Inc.” 
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cancer therapy methods such as chemotherapy, radiation, and/or surgery are known to 
be limited by drug resistance, severe side effects, lack of efficiency. Thus seeking for 
new methods to treat cancer, as well as modifying the existing methods, could bring 
new hope to the field of cancer therapy. The potentials and limitations of two rather 
new methods of cancer therapy, cancer gene therapy and gene directed enzyme 
prodrug therapy are going to be discussed in this thesis. 
 
1.2 Cancer gene therapy 
 
Gene therapy is a method of using therapeutic genes instead of traditional drugs. The 
first clinical cancer gene therapy took place in 1989 when tumor-infiltrating 
lymphocytes (TIL) were engineered with a DNA marker through retroviral transduction 
in people with deadly Melanoma [2]. The therapy was considered successful in all cases 
without noted side effects. Since then, gene therapy has become one of the major 
advancing methods to treat several cases of almost all cancer types. Cancer diseases 
currently possess the largest portion of trials among all diseases, with the total number 
of 1415 trials (64%) worldwide [3]. A wide variety of problems with cancer 
chemotherapy, such as drug resistance and side effects, could be targeted or modified 
with gene therapy, through various therapeutic agents, and vectors. Having said that, 
one must bear in mind that it is critical for the therapeutic gene to be delivered with the 
right amount to the tumor site. This could be an issue due to short half-lives of the 
therapeutic genes as well as blood barriers in the body. One way of dealing with this 
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issue could be using a proper targeting method. It was not until the discovery of carrier 
cells that the issues with delivery and dosage of the therapeutic agents were addressed. 
Mesenchymal stem cells are probably the most commonly used cells among all carriers 
[4-6]. 
 
1.3 Mesenchymal stem cells as carriers in cancer therapy 
 
Mesenchymal stem cells exhibit intrinsic tumor-tropic properties and therefore are 
considered as ideal carriers for therapeutic agents including genes, nanoparticles, etc. 
to be delivered to tumor site. The first study that demonstrated migratory properties of 
genetically engineered MSCs was done on a rat glioma model [4]. In this study, an 
adenoviral vector utilized the delivery of Interleukin-2 (IL-2) into mesenchymal stem 
cells as carriers, which resulted in prolonged survival of glioma bearing rats. Since then, 
numerous studies have demonstrated tumor-homing properties of mesenchymal stem 
cells toward both primary and metastatic sites [5, 6]. The promise of MSCs being used 
as carriers for anticancer agents has recently made its way through various pre-clinical 
models [7]. The recent excitement of mesenchymal stem cells as therapeutic vehicles 
shows their significance in targeting the delivery issues affiliated with therapeutic 
reagents such as their short half-lives and blood barriers. MSCs facilitate a rather 
controlled delivery and release of these reagents at the site of tumor.  
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1.4 Therapeutic agents in cancer gene therapy 
 
Many anticancer agents are interleukins such as IL2, IL7, and IL12 that employ an 
immunostimulatory mechanism to face tumor cells [8]. In almost all cases of Interleukin 
delivery, the therapeutic agents activate the lymphocytes and natural killer cells against 
the tumor. Interleukins have been proven to increase apoptosis and prevent metastasis 
into other organs in numerous tumors such as melanoma, glioma, breast and hepatoma 
cases [4, 9]. A case of rat glioma was treated with interferon gamma (IFNγ) through 
autologous transduction of tumor cells [10]. The effect of cytokine was then boosted 
with delivery of IL-7 through mesenchymal stem cells (MSCs) in the same study. The 
density of T-cells observed in the case was reported higher than treated animals with 
either method only suggesting that the therapeutic effects depend on the response of 
T-cells. In other studies, MSCs engineered to express IL-12 have been reported to have 
antitumor effects on mice bearing carcinoma [11] and cervical tumors [12]. MSCs 
mediated with IL-2 were also reported effective on both mouse bearing glioma [4] and 
melanoma tumors [13]. MSCs expressing CX3CL-1 have also have been reported 
effective in inhibition of lung tumor metastasis [14].  
Interferons such as IFN-α and IFN-β have also been shown to have immunostimulatory 
and apoptosis inducing effects on various tumor models [5-18]. Ren et al. treated lung 
metastasis of melanoma with IFN-α expressing MSCs, in a mouse model [15]. The 
treatment resulted in prolonged survival of mice and reduced growth of melanoma and 
lung metastasis. Kidd et al. studied the effects IFN-β expressing MSCs on pancreatic 
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PANC-1 carcinomas in a mouse model. The results showed homing of mesenchymal 
stem cells to primary and metastatic pancreatic tumors as well as tumor growth 
inhibition. 
Tumor necrosis factor-related apoptosis induced ligand (TRAIL) is a pro-apoptotic 
protein that has been reported to successfully induce apoptosis in numerous glioma 
models [19-21]. MSCs engineered to secrete TRAIL have also shown to be effective with 
other tumor models such as lung, breast, colon, and pancreas tumors [22-26].  
NK4 is a growth factor antagonist that has been reported to have effective angiogenesis 
inhibition results on colon tumor and lung metastasis models [27]. The study shows 
significant prolonged survival of C-26-tumor-bearing mice treated with NK4 expressing 
MSCs.  
Genetically engineered mesenchymal stem cells have already gone a long way in the 
advancement of cancer gene therapy, and have been deployed in various studies as 
therapeutic carriers. As bright and promising the perspective of cancer gene therapy 
with mesenchymal stem cells might look, it is still shattered by efficiency and safety of 
gene delivery methods. 
 
1.5 Gene-directed enzyme prodrug therapy 
 
Gene directed enzyme prodrug therapy (GDEPT) is a method of converting rather non-
toxic prodrugs to cytotoxic form using genes encoding prodrug activation enzyme. The 
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method was established in order to selectively target the tumor cells by locally 
activating the prodrug. The efficiency of the technique however, was hindered with low 
transfer efficiency of the suicidal genes in clinical trials [28, 29]. It is noteworthy that 
although not all tumor cells can be effectively transfected with the transgene, the 
insufficiency of gene transfer can be contemplated with the bystander effect which will 
result in the death of not only the transfected cell, but also the neighboring tumor cells 
[30]. Figure 1.2 depicts a schematic of GDEPT [31]. Just like gene cancer therapy, the 
issue with low gene delivery could be targeted with carrier cells such as mesenchymal 
stem cells.  
The role of stem cells as gene carriers for GDEPT was first investigated in conversion of 
5-fluorocytosine (5-FC) to its highly toxic form 5-fluorouracile (5-FU) using migratory 
neural stem cells (NSCs) [32]. Since then many studies have been conducted on 
efficiency of MSCs as gene carries for GDEPT and their role in eliciting bystander effect.  
Some commonly used prodrug-gene pairs could be listed as cytosine deaminase (CD) 
with 5-FC [33,34], herpes simplex virus thymidine kinase (HSV-TK) to activate ganciclovir 
(GCV) [35,36], and carboxylesterase genes (CE) with camptothecin-11 (CPT-11) [37] and 
have already been tested on various tumor models such as ovarian, brain, colon, and 
prostate tumors and also have made their ways through clinical trials [38]. 
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Figure 1.2 Schematic of gene directed enzyme prodrug therapy (GDEPT). Touati et al., 2011. © 2011 
Touati W, Beaune P, De Waziers I. Published in [31] under CC BY 3.0 license. Available 
from: http://dx.doi.org/10.5772/24788   
 
1.6 Gene delivery methods  
 
The efficiency of both methods (cancer gene therapy and GDEPT) discussed so far is 
limited by proper targeting and gene delivery method. Engineering mesenchymal stem 
cells genetically, and using them as targeting and delivery systems, is one of the 
techniques to address the limitations of both methods. The significance of genetically 
engineered mesenchymal stem cells in cancer therapy is more distinct with numerus 
studies done deploying them as carriers of therapeutic agents. Nevertheless, the 
effectiveness of MSCs as targeted drug and gene carriers is narrowed by gene 
transfection and expression efficiency. Despite all advances in gene delivery, almost 
none of the techniques tried on mesenchymal stem cells can be considered ideal due to 
limits and risks associated with almost all methods of delivery. Gene delivery methods 
are normally categorized as viral (using viruses for gene delivery) and non-viral 
(including physical and chemical approaches) methods. 
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Viral vectors are considered more efficient in terms of efficiency of gene expression, but 
more risky on the other side. Non-viral vectors however, are mostly associated with 
lower expression efficiency and with cytotoxicity side effects in most cases. Having said 
that, more and more studies are focusing on modification of non-viral delivery methods 
due to their numerous advantages such as unrestricted plasmid size, ease of synthesis, 
and lower risks for clinical applications. 
 
1.6.1 Viral vectors 
 
Viral vectors are known for their high risk of immunogenicity and restricted size of 
packing DNA. In case of cancer therapy however, most of the studies have introduced 
the transgene to mesenchymal stem cells through viral vectors as a consequence of 
their high efficiency. Concerns about usage of viral vectors increased when the first 
clinical case of fatality occurred in 2000 [39]. One answer to the failure of the case was 
that if repeated administration of the virus had led to immunological rejection and the 
amount of virus administrated to the patient was “simply too much” [39].  Although the 
failure of gene therapy trial in 2000 has not been repeated thus far, concerns still remain 
the same about usage of viral vectors in gene delivery. Nevertheless, the majority of 
current clinical trials have used a viral vector known as adenovirus (22.2%) for gene 
delivery [3]. Adenoviral vectors have been reported as effective gene carriers and have 
been deployed in almost all methods of gene therapy for cancer [40]. They are known 
for their relatively higher potential of package capacity in comparison to other viruses 
  
9 
  
as well as their immunogenicity concerns. Adenoviruses also tend to integrate into 
cellular genome that would lead to loss of genetic information after few divisions of 
transduced cells [41].  
A high percentage of all gene therapy clinical trials, about 18.4%, have used retroviruses 
[1, 3, and 42]. Their long term expression efficiency makes them attractive delivery 
vectors. Retroviruses also disadvantage from relatively small packaged genetic 
information as well as uncontrolled integration of virus in the genome, which could 
potentially cause malignant transformation induction [41]. These concerns have led to 
a significant decrease in usage of retroviruses in clinical trials over the past decade. 
With a lower number of clinical trial cases, other viral vectors have also been used for 
gene delivery such as lentivirus and vaccinia virus [3].  
Having high transfection efficiency is the main reason behind using viral vectors for gene 
delivery, nevertheless, safety concerns regarding administrating high amounts of 
viruses in clinical trials have drawn researchers’ attention toward non-viral vectors 
recently. 
 
1.6.2 Non-viral vectors 
 
At the beginning of gene delivery era, non-viral vectors received less attention than viral 
vectors, due to their rather poor efficiency in expression of the transgene. Yet it is 
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known that non-viral vectors are relatively easier to synthesize, advantage with low 
immune response and almost no biosafety concern. During the past decade, more 
studies were conducted with non-viral vectors. Among all non-viral vectors used for 
gene delivery, lipofection has most of the current trial cases with a total number of 115 
cases [3]. Non-viral vectors seem to have a much higher potential in the future, 
nonetheless, it is important to know that there are still many barriers in non-viral 
delivery methods that need a great deal of modification [43]. Here some of the most 
commonly used non-viral vectors are reviewed and their gene transfection efficiency 
on mesenchymal stem cells are compared along with their safety concerns.  
 
1.6.2.1 Polyethyleneimine 
 
Polyethyleneimine (PEI) based particles have been extensively used as carrier for gene 
delivery. Various types (linear and branched) and molecular weights of PEI have been 
tested for gene delivery purposes [44]. The most effective is known to be branched PEI 
with the molecular weight of 25kDa, which is usually used as a reference to check the 
efficiency of other non-viral vectors. There is however, cytotoxicity concerns associated 
with PEI vector. Gene delivery with PEI/DNA particles is usually done through various 
ratios of primary amine groups in PEI molecule to phosphate in pDNA, also known as 
N/P ratio. Regularly, higher N/P ratios would result in higher expression efficiency a long 
with higher cytotoxicity caused by PEI.  
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PEI/DNA polyplexes were reported to be most effective at N/P ratio of 16, transfecting 
rat bone marrow derived mesenchymal stem cells [45]. Nevertheless, the cytotoxicity 
of PEI at this N/P ratio remained a concern. Another study, reported the highest 
efficiency of PEI/DNA transfection on human adipose tissue derived MSCs at N/P ratio 
of 8 [46]. Transfection efficiency and cytotoxicity of the polyplexes were compared to 
Lipofectamine through flow cytometry and MTT assay. PEI/DNA polyplexes at NP ratio 
of 8 were reported as more efficient than Lipofectamine.  
Lower molecular weights of PEI are known to have lower cytotoxicity on cells as well as 
lower expression efficiency. Some studies have tried to take advantage of this lower 
toxicity and overcome the efficiency issue, functionalizing the polymer with other 
reagents. Hu et al. [47] modified PEI600 by linking the polymer with β-cyclodextrin (β-CD) 
and used the vector to introduce tumor necrosis factor (TNF)-related apoptosis-
inducing ligand to MSCs. Genetically engineered MSCs were used as cellular vehicles to 
deliver therapeutic agents to lung metastasis model in rats. The transfection efficiency 
of PEI600-Cyd (N/P=20) was compared with PEI 25kDa (N/P=10) and was shown to be 
comparable through Luciferase activity assay. Furthermore, their MTT assay results 
showed much higher viability for PEI600-Cyd nanoparticles in comparison to PEI 25kDa, 
leading to a conclusion that PEI600-Cyd nanoparticles are safer and more efficient 
delivery systems. Their results also showed a significant decrease in metastasis in vivo 
with almost no toxicity [47]. 
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An alternative study uses graft copolymer, PEG8k-PEI25k, as gene delivery system to rat 
mesenchymal stem cells [48]. The transfection efficiency of the synthetic polymer at 
various N/P ratios was compared to commercially available cationic liposome. The 
highest efficiency associated with N/P ratio of 40, higher than the cationic lipid, 
decreasing with further increase of N/P ratio due to high toxicity.  
 
1.6.2.2 Spermine-pullulan  
 
Cationized Pullulan has been demonstrated as an effective gene carrier to mesenchymal 
stem cells [49]. Zhang et al. [50] investigated the efficiency of mesenchymal stem cells 
transfected with spermine-pullulan on pulmonary melanoma metastasis in vivo using 
ganciclovir-thymidine kinase (GCV-TK) as the GDEPT (Gene Directed Enzyme Prodrug 
Therapy) system. Genetically engineered MSCs were shown to migrate toward tumor 
and elicit bystander effect in presence of GCV. The gene expression efficiency of the 
cationic polymer (at N/P=3) was compared to PEI (N/P=5) as a non-viral gene delivery 
reference through Luciferase activity assay and the results were reported to be 
comparable. The cytotoxicity of PEI/DNA particles at N/P ratio of 10 was reported to be 
higher than SP particles at N/P ratio of 3 [50]. In an alternative study, a reverse 
transfection method was used to transfect MSCs with spermine-pullulan, which 
resulted in significant prolonged gene expression in comparison to the conventional 
method [51]. 
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1.6.2.3 Chitosan 
 
Chitosan is the most commonly used natural polymer for gene delivery due to its 
biocompatibility and positive charge. In a comparative study, Chitosan-DNA 
nanoparticles were employed as gene carriers for transfecting human mesenchymal 
stem cells (MSCs), human osteosarcoma cells (MG63) and human embryonic kidney 
cells (HEK293) [52]. The efficiency and safety of the transfection were compared with 
commercially available cationic lipid, LipofectamineTM 2000 (LF). Results varied for each 
cell line, however indicated lower transfection efficiency comparing to LF in all cases. 
Chitosan-DNA nanoparticles on the other hand, showed much higher viability in 
comparison to LipofectamineTM 2000. 
 
1.6.2.4 Poly-L-lysine 
 
Poly-L-lysine (PLL) was one of the first non-viral vectors tested for gene delivery. The 
efficiency of the cationic polymer as gene carrier for bone marrow stromal cells (BMSC) 
was investigated using PEI as a reference [53]. The study revealed that the cationic 
polymer PLL was a less efficient gene carrier as a result of poor cellular uptake in 
comparison to PEI. 
 
1.6.2.5 Poly (amidoamine) 
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Poly (amidoamine) (PAMAM) is a type of dendrimer with repeated amine and amide 
groups in their branches. They are known to be effective and non-toxic gene carriers. 
The transfection efficiency of mesenchymal stem cells transfected with PAMAM and the 
reporter gene β-galactosidase was reported as low in a recent study [54]. Another study 
compares various commercially available types of polymers including two commercially 
available reagents Poly-Fect® and SuperFect®. The transfection efficiency was reported 
lower than Lipfectamine 2000TM [55]. 
 
1.6.2.6 Cationic lipids  
 
Cationic Lipids are known for their high transfection efficiency. They come in a wide 
range of commercially available transfection reagents often used as references for 
studying the efficiency of other non-viral vectors.  Mesenchymal stem cells were 
transfected with three different lipid-base, commercially available vectors, 
Lipfectamine 2000, Metafectene, and Lipofectamine plus [56]. Lipfectamine 2000 was 
reported to have the highest efficiency, followed by Metafectene and Lipofectamine 
plus respectively. Reported results from cell viability assay was about 80% and almost 
the same in all three cases. 
In another study, transfection efficiency and safety of mesenchymal stem cells isolated 
from human, rat and rabbit were compared using Lipfectamine 2000TM as transfection 
reagent [57]. Human and rat MSCs were reported to have relevant expression at each 
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time interval. However, rabbit MSCs showed lower efficiency. All cases of study showed 
similar cell viability. Nuclear localization sequence (NLS) was reported to have 
significant improvement on gene expression.   
 
1.6.2.7 Calcium-phosphate precipitation 
 
Calcium phosphate (CP) nanoparticles are inorganic nanoparticles with high potentials 
for gene delivery [58, 59]. In a recent study calcium phosphate nanoparticles were 
employed to deliver the plasmid transforming growth factor beta 1 (TGF-β1) to MSCs 
[60]. Enzyme-linked immunosorbent assay and MTT assay were preformed to compare 
the expression efficiency and cytotoxicity between calcium phosphate nanoparticles 
and Lipofectamine™ 2000. The transfection efficiency of CP nanoparticles was reported 
to be comparable Lipofectamine™ 2000 as the CP nanoparticles showed lower toxicity. 
 
1.6.2.8 Standard electroporation 
 
Electroporation is a physical technique of delivering DNA into cell cytoplasm through 
the cell membrane. The method itself is known to be harsh, leaving transfected cells 
with low viability.  However, some studies have tried to boost the transfection efficiency 
and cell viability through modification of the technique, leading to rather high 
transfection efficiency along with much less toxicity [61, 62]. A recent comparative 
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study was conducted to investigate transfection efficiency of calcium phosphate 
precipitation, cationic polymer (TurboFect Transfection Reagent), standard 
electroporation, and Microporation on Human Adipose-derived mesenchymal stem 
cells [63]. The expression efficiency of hAD-MSCs was reported as very low (about 1%) 
in all cases (including calcium phosphate) excluding Microporation, which revealed up 
to 50% expression efficiency. 
 
Table 1.1 a review of effective non-viral delivery methods and their limitation 
  Delivery Method Limitation 
  PEI [45-47] Fair efficiency, Cytotoxicity 
 Cationic Lipids [56, 57]  Fair efficiency, 
Immunogenicity in some 
cases 
Spermine-Pullulan [49-51] Fair efficiency (comparable to 
PEI) 
Chitosan [52] Low efficiency (Lower than 
Lipofectamine), Low solubility 
Poly-L-lysine (PLL) [53] Low efficiency (Lower than 
PEI), Low cellular uptake  
Poly (amidoamine) or 
PAMAM [54,55] 
Complement activation, low 
efficiency (Lower than 
cationic lipids) 
Calcium-phosphate 
precipitation [60] 
Low efficiency (comprable to 
Lipofectamine) 
Standard electroporation [63] Tissue damage, Limited 
Accessibility of electrodes to 
internal organs 
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1.7 Conclusion 
 
Gene therapy is an evolving field, which provides advantages on treatment against 
numerous diseases, especially cancer. Mesenchymal stem cells are known for their role 
in regenerative medicine and have been widely used in cancer therapy, Due to their 
tumor-homing properties. MSCs have mostly been deployed as anti-tumor delivery 
vehicles in order to address the delivery issues in a lot of cancer types. However, 
genetically engineering MSCs remains an issue, as both viral and non-viral methods have 
shown to have their own limitations. Viral vectors are mostly known to be more 
effective, yet there are always safety concerns associated with their usage. Non-viral 
vectors on the other hand, are known for their safety and relatively lower efficiency. 
The non-viral vectors reviewed in this chapter are some of the most commonly used 
and effective vectors for gene delivery. However, none of these vectors can be 
considered as ideal carriers and each one of them has their own concerns and 
limitations. Some of the limitations associated with these vectors are listed in a recent 
review [64]. Table 1.1 summarizes non-viral vectors used for MSCs along with their 
concerns and limits. These results lead us to the conclusion that none of the non-viral 
vectors used for gene delivery to MSCs is ideal and satisfies the needs in cancer therapy. 
In the next two chapters, calcium alginate nanoparticles are synthesized and used as 
gene carriers to mesenchymal stem cells. The transfection efficiency and safety of the 
nanoparticles were compared to various N/P ratios of PEI/DNA polyplexes. The 
  
18 
  
expression efficiency of MSCs was studied through fluorescence microscopy as well as 
flow cytometry.  
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Chapter 2   Synthesis of Calcium Alginate Nanoparticles 
 
2.1 Introduction 
 
Natural biopolymers such as polysaccharides have shown promising results in the field 
of drug and gene delivery [65, 66]. Their significance lies within their biocompatibility, 
biodegradability, and low toxicity.  Calcium alginate nanoparticles have been reported 
as efficient, polysaccharide based, drug and gene carriers [67, 68].  In general, one of 
the aspects that shatters the efficiency of non-viral drug and gene carriers is their wide 
distribution in size. Various methods have been reported for preparation of calcium 
alginate nanoparticles [67-69]. Among all, the method presented by You et al. [67], 
water in oil reverse microemulsion, seems to be the most efficient technique for gene 
delivery as a result of smaller particles size range. The particles obtained in this 
technique are in a small size range which facilitates endocytosis cellular uptake. In this 
method, the dispersed alginate droplets (water phase), are stabilized by a surfactant 
dioctyl sulfosuccinate sodium salt (AOT). Calcium alginate nanoparticles are then 
formed by crosslinking Ca+2 with alginate molecules in the interphase. The final 
nanoparticles have a core of sodium alginate as well as a shell of calcium alginate soft 
gel. Figure 2.1 depicts schematic of how the nanoparticles are synthesized. In this 
chapter, calcium alginate nanoparticles were synthesized using the reverse 
microemulsion system. A ternary phase diagram was generated for the microemulsion 
system to study the effects of chemical compositions of the microemulsion system on 
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the size range of the nanoparticles. Scanning electron microscopy as well as dynamic 
light scattering characterized the alginate particles prepared for gene delivery to 
mesenchymal stem cells.    
 
2.2 Materials and methods 
 
2.2.1 Effects of emulsion system ratio on calcium alginate particle size 
 
To study the effects of chemical 
composition on the size of calcium 
alginate nanoparticles, a ternary 
phase diagram was generated for 
the microemulsion. In order to 
generate the diagram, 10 different 
ratios of AOT (surfactant), and 
toluene (oil phase) solution were 
picked. Sodium alginate solution 
(o.5%w/w) was then added drop-
wise to each solution until three 
different phases were apparent (transparent-translucent-opaque). The diagram was 
obtained right at the border of the visual transition from transparent to turbid. Next, 
Figure 2.1 Schematic diagram of calcium alginate nanoparticles 
preparation 
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one point from each region was selected to study the size of the nanoparticles using a 
dynamic light scattering device (Malvern, Zetasizer Nano ZS, UK).  
 
2.2.2 Preparation of calcium alginate nanoparticles for gene delivery 
 
Calcium alginate nanoparticles were prepared using a reverse micro-emulsion method 
[67]. To make particles within size range of 100-200 nm, a micro-emulsion system was 
prepared containing 94.5%toluene which was used as the oil phase, 4.9% surfactant, 
dioctyl sodium sulfosuccinate (AOT), and 0.57% sodium alginate solution. Briefly, 0.05 
g medium viscosity sodium alginate salt was dissolved in 10 ml of DI water to obtain 
0.5%w/w solution. 250 mg of the surfactant, AOT, was pre-dissolved in 15.12 ml toluene 
as the oil phase. 10 µl of the prepared alginate solution was then added drop-wise to 
toluene/AOT solution. The micro-emulsion was then mixed properly and left to 
equilibrate for about 10 minutes. To form the calcium alginate nanoparticles 2 ml of 2% 
w/w calcium chloride solution was then added drop-wise to the emulsion under 
agitation. The nanoparticles were formed by crosslinking Ca+2 in the interphase of the 
emulsion. The system was then left for one hour and the nanoparticles were then 
collected by ultra-centrifugation at 15300 rpm for 60 minutes. To wash off the residual 
toluene and surfactant, the nanoparticles were washed with water/acetone solution 
(1:1 ratio) three times and collected with ultra-centrifugation at 15,300 rpm for 60 
minutes. In order to minimize the toxicity, the collected nanoparticles were washed 
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with DI water only, before addition to MSCs. To get gene-loaded nanoparticles, 10 µl 
GFP-encoding plasmid was pre-added to the sodium alginate solution.  
 
2.2.3 Characterization of calcium alginate nanoparticles prepared for gene delivery 
 
To characterize the size of calcium alginate nanoparticles, the pre-collected particles 
were re-suspended in about 1ml of DI water and the size was measured using a dynamic 
light scattering device (Malvern, Zetasizer Nano ZS, UK). The nanoparticles were also 
characterized through scanning electron microscopy. A drop of re-suspended 
nanoparticles was placed on a piece of aluminum foil. The droplet was then left to air-
dry overnight. The foil was placed on a specimen and coated Pt/Pd alloy for 5 
nanometers (Anatech, Hummer 6.2, USA). All images were taken at 10 KV at a working 
distance of 5 mm. 
 
2.3 Results and discussion 
 
2.3.1 Ternary phase diagram 
 
Figure 2.2 depicts the obtained phase diagram for the micro-emulsion system as well as 
a picture from the solutions at all three points. Point A on the phase diagram is assigned 
to the composition of 92% toluene, 7.14% AOT, and 0.85% sodium alginate solution. 
Point B is obtained as more sodium alginate is added to the system (90.81% toluene, 
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7.14% AOT, 2.04% sodium alginate). Addition of more sodium alginate, will take the 
micro-emulsion system to point C (89% toluene, 7.14% AOT, 3.85% sodium alginate), 
which is the turbid phase region. Figure 2.3 shows the size distribution results of 
nanoparticles prepared with compositions of point A and B and C. It can be seen that 
the size of the nanoparticles increases by moving from transparent region to opaque.  
 
 2.3.2 Size and morphology of the nanoparticles prepared for gene delivery 
 
Figure 2.4 shows results of scanning electron microscopy as well as dynamic light 
scattering results. Nanoparticles are shown to be in the size range of 150-200 ±50 nm 
based on SEM results. The morphology of the nanoparticles is shown to be roughly 
spherical. The average size reported by DLS is about 150 nm which is in agreement with 
SEM results. It is notable that the nanoparticles were passed through a 0.45 μ syringe 
filters only before cellular transfection. The nanoparticles obtained for size and 
morphology studies were not filtered.  
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Figure 2. 2 Ternary plot for the microemulsion system. Toluene is the oil phase, the 0.5% 
sodium alginate solution is the water phase, and AOT is the surfactant. Point A 
(92:0.85:7.14) is located in the transparent zone. Point B (90.81:2.04:7.14) is on the 
transluscent line, and point C (89:3.85:7.14) takes place in the turbid phase region. 
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Figure2.3 Size distribution (by intensity and volume) of calcium alginate nanoparticles obtained from 
transparent, translucent, and turbid regions- Pont A (92:0.85:7.14), B (90.81:2.04:7.14), C 
(89:3.85:7.14) of the ternary phase diagram. 
Figure 2. 4 Characterization of calcium alginate nanoparticles through SEM and dynamic light scattering. 
a,b) dynamic light scattering results c) SEM images for calcium alginate nanoparticles. The nanoparticles 
were coated with Pt/Pd prior to imaging (~5 nm). Image was taken at 10 kV and working distance of 5 
nm. 
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2.4 Conclusion 
 
Calcium alginate nanoparticles in the size range of 100-200 nanometers were 
successfully synthesized for gene delivery, using reverse micro-emulsion method. The 
size and morphology of nanoparticles were characterized using scanning electron 
microscopy as well as dynamic light scattering. The behavior of micro-emulsion system 
was studied through a ternary phase diagram. The diagram was generated using 10 
different points of various compositions, right at the interface of phase change from 
transparent to turbid. The size of particles obtained from each phase region was 
measured using dynamic light scattering. The nanoparticles grew in size while moving 
from transparent region to turbid.  
 
 
 
  
  
 
 
 
 
 
  
1The material contained in this section will be submitted for publication. 
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Chapter 3   Transfection of Mesenchymal Stem Cells with Calcium Alginate 
Nanoparticles1 
 
3.1 Introduction 
 
Mesenchymal stem cells have gained extensive attention through the past decade due 
to their properties of isolation and expansion in vitro, self-renewal, along with their 
differentiation potential which make them ideal for tissue engineering. Additionally, a 
lot of researchers have taken advantage of their special tumor-homing properties for 
targeted cancer therapy [70]. Some studies have also reported antitumor effects of 
MSCs in various tumor models [71, 72]. Thus genetically engineered MSCs seem to be 
ideal gene carriers for gene directed enzyme prodrug therapy (GDEPT) or cancer 
immunotherapy. MSCs engineered with genes such as cytosine deaminase (CD) [33, 34], 
herpes simplex virus thymidine kinase (HSV-TK) [35, 36] have already been used in a lot 
of studies to perform a tumor specific therapy by transforming the fairly non-toxic 
prodrugs 5-fluorocytosine (5-FC) and ganciclovir (GCV) into their toxic suicidal form. On 
the other hand, studies have shown that interleukins can be secreted by genetically 
engineered MSCs in order to activate the natural killer cells at tumor site [4, 8, and 9]. 
Gene transfer to MSCs can be done through viral and non-viral vectors. Adenovirus and 
retrovirus are the most commonly used viral vectors for gene 
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transduction [40, 42]. Viral methods of gene delivery, although more effective, are 
known to have a high risk of toxicity, and immunogenicity of the virus itself [73]. In 
comparison, non-viral methods are known for their biosafety, relative ease of synthesis, 
unrestricted plasmid size, low toxicity, but lower expression efficiency as well. Recently, 
more studies are trying to overcome the efficiency concerns of non-viral vectors as an 
alternative method. 
Biocompatibility, biodegradability, ease and low cost of synthesis are the main reasons 
calcium alginate nanoparticle are attractive drug and non-viral gene carriers. Alginate 
particles with a size range between 80 to 1,000 nm have been reported to have gene 
and drug delivery potentials [69, 67, and 74].  
PEI based particles are known to be one of the most effective non-viral gene delivery 
systems. Due to its relatively high expression efficiency, PEI is usually used as a 
reference in studying non-viral gene delivery systems. It is however, known that the 
delivery system is also associated with cytotoxicity issues due to positive charge of PEI. 
Gene delivery is done through the polyplexes formed by PEI/DNA molecules. Normally, 
with higher N/P ratios, a higher expression efficiency and cytotoxicity is expected. In 
this chapter, mesenchymal stem cells are transfected with calcium alginate 
nanoparticles and different N/P ratios of PEI/DNA polyplexes as a reference. A 
comparative study was conducted for the efficiency and safety of transfections using 
fluorescence microscopy, flow cytometery, and viability assays.  
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3.2 Materials and methods 
 
3.2.1 Culturing mesenchymal stem cells 
 
Human bone marrow-derived mesenchymal stem cells (HBMSCs) were obtained from 
RoosterBio (Frederick, MD, USA). Cells were cultured in alpha minimum essential media 
(α-MEM), and 20% fetal bovine serum (FBS), with 2% L-glutamine and 1% penicillin 
streptomycin under normal culture conditions of 37°C and 5% CO2. 
 
3.2.2 Preparation of PEI/DNA polyplexes 
 
N/P ratios of 1, 5, 7, 10, and 20 were studied to compare the cytotoxicity of PEI as well 
as efficiency of the gene transfection. To prepare the PEI/DNA conjugates 100 µl of α-
MEM was placed into 6 different micro centrifuge tubes. 25k PEI was dissolved in DI 
water to get 0.2 µg/ µl concentration. 1, 5, 7, 10, and 20 µl of PEI solution were added 
to α-MEM to obtain N/P ratios of 1, 3, 5, 7, 10, and 20, respectively. 10 µl GFP plasmid 
was added afterwards to each micro centrifuge tube. To make the transfection 
efficiency comparable to calcium alginate nanoparticles, the amount of GFP added was 
kept constant in all cases. The mixture was then incubated in room temperature for 20 
minutes.  
 
3.2.3 Transfection of mesenchymal stem cells 
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About 10,000 MSCs were seeded in each well of three six well plates from their third 
passage. After 24 hours, calcium alginate nanoparticles were added to the culture wells 
along with PEI/DNA polyplexes. To minimize toxicity, the growth medium in all wells 
were changed after 24 hours of transfection. The expression of the marker gene was 
later checked under a fluorescence microscope after 24, 48, and 72 hours for both 
calcium alginate particles and different N/P ratios of PEI/DNA polyplexes. At 24, 48, and 
72 hours the cells were brought up in media and collected using 0.25% trypsin/EDTA. 
The collected cells were then re-suspended in PBS and saved in -20°C for 2 days prior to 
quantitative investigation with flow cytometry. 
 
3.2.4 Viability assay 
 
The viability of transfected mesenchymal stem cells was determined with trypan blue 
assay. 72 hours after transfection of mesenchymal stem with Ca-alginate nanoparticles 
and PEI/DNA polyplexes, cells were collected for viability tests. A non-transfected 
sample of MSCs was kept as a control group. For each sample, about 20 μl of 
resuspended cells were placed on a slide and the same volume of 0.4% trypan blue 
solution was added to each sample. The viable cells were then counted under the 
microscope using a hemocytometer.  
3.3 Results and discussion 
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3.3.1 Fluorescent microscopy results  
 
Figure 3.1 shows bright field and fluorescent images captured at 24, 48 and 72 hours 
after transfection. The time frames of 24, 48, and 72 hours were chosen to observe the 
expression efficiency of MSCs in a rather wider range of time. In addition, it is 
hypothesized that the endosomal escape of calcium alginate nanoparticles would occur 
sometime between 12-48 hours after transfection, and therefore the experiment was 
designed in a way to include the hypothesized endosomal escape time frame. 
Furthermore, it is known that PEI has cytotoxicity issues, and it would   be valuable to 
see the effects of its cytotoxicity on the GFP expression for MSCs. The GFP expression 
can be observed as brighter spots in the images. It can be seen from the images that 
higher N/P ratios result in higher GFP expression. It is also visible that the expression 
efficiency almost drops off with time in samples transfected with PEI. Samples 
transfected with calcium alginate nanoparticles show lower expression at the beginning 
after 24 hours, however, a higher GFP expression is observed after 48 hours.  
 
3.3.2 Flow cytometry results 
 
Figures 3.2 and 3.3 represent comparative results between calcium alginate 
nanoparticles and PEI/DNA polyplexes with N/P ratios of 1, 5, 7, 10, and 20 respectively. 
As can be seen from the figure, fluorescent intensity of GFP expressing MSCs, 
transfected with calcium alginate nanoparticles, follow a time dependent upward trend. 
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For PEI transfected MSCs however, an opposite pattern can be observed. The upward 
manner of calcium alginate nanoparticles with time can be correlated to the endosomal 
escape of plasmid DNA after internalization of the particles into the endolysosome. It is 
hypothesized that the endosomal escape of the plasmid happens between 12-48 hours 
which could justify the delayed expression of the gene. On the contrary, the time 
dependent fall, observed with PEI, can be correlated with the cytotoxicity of the gene 
Figure 3.1 Mesenchymal stem cells transfected with green fluorescence protein bright field and fluorescent 
images. a-f) MSCs 24 hours after transfection using calcium alginate and N/P ratios of 1, 5, 7, 10 and 20 of 
PEI/DNA respectively. g-l) MSCs 48 hours after transfection using calcium alginate and N/P ratios of 1, 5, 7, 
10 and 20 of PEI/DNA respectively. m-r) MSCs 72 hours after transfection using calcium alginate and N/P 
ratios of 1, 5, 7, 10 and 20 of PEI/DNA respectively. 
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carrier. As expected, MSCs show higher gene expression when transfected with higher 
N/P ratios of PEI/DNA polyplexes. Figure 3.3 depicts the histogram results of flow 
cytometry.  
 
3.3.3 Viability assay  
 
Figure 3.4 shows the results of the viability test for both alginate nanoparticles and 
PEI/DNA polyplexes.  As can be observed from the figure, PEI/DNA polyplexes show very 
low toxicity at N/P ratios of one to five. However, as the N/P ratio goes up, higher 
toxicity is observed. At N/P ratio of 20, less than half of the cells were considered viable. 
This justifies the results obtained from flow cytometry.   
Figure 3.2 Flow cytometry results, the fluorescent intensity of GFP expressing MSCs 
transfected with calcium alginate nanoparticles in comparison to PEI/DNA polyplexes, N/P 
ratios of 1, 5, 7, 10, and 20. MSCs were collected for flow cytometry testing after 24, 48, and 
72 hours. 
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Figure 3.3 Flow cytometry histogram results, the GFP expression of MSCs transfected with calcium 
alginate nanoparticles in comparison to PEI/DNA polyplexes, N/P ratios of 1, 5, 7, 10, and 20. MSCs 
were collected for flow cytometry analysis after 24, 48, and 72 hours. 
 
Figure 3.4 Viability of mesenchymal stem cells 72 hours after transfection with 
calcium alginate nanoparticles and various N/P ratios of PEI/DNA. 
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3.4 Conclusion 
 
In this chapter, human bone marrow derived mesenchymal stem cells were successfully 
transfected with GFP using calcium alginate nanoparticles as gene carriers. The 
efficiency and safety of the transfection was compared to five different N/P ratios of 
PEI/DNA as a reference. Calcium alginate nanoparticles showed an upward trend in 
efficiency within 72-hour time frame. PEI/DNA polyplexes however, showed less 
expression with time, as a result of their toxicity. The fluorescent intensity of GFP 
expressing MSCs, transfected with calcium alginate nanoparticles was shown to be 
comparable to all N/P ratios of PEI. However, a rather low cell viability is observed with 
N/P ratios higher than 10. On the contrary, calcium alginate nanoparticles were shown 
to have very low toxicity. In conclusion, calcium alginate nanoparticles can be 
considered safer carriers for gene delivery to mesenchymal stem cells with comparable 
transfection efficiency.  
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Chapter4   Conclusion 
 
Genetically engineered mesenchymal stem cells are proven to be valuable tools for 
targeted drug and gene delivery in cancer therapy. Yet, the tools provided to do such 
engineering of mesenchymal stem cells are limited and associated with various issues. 
The main concern with viral vectors is immunogenicity, while non-viral vectors are 
mostly less effective and in some cases cytotoxic. Calcium alginate nanoparticles are 
known for their high potentials in drug and gene delivery. Due to their natural structure, 
they are also considered non-toxic. In this study, we first synthesize calcium alginate 
nanoparticles using reverse microemulsion method. Next we investigate the efficiency 
and safety of calcium alginate nanoparticles for gene delivery to mesenchymal stem 
cells. As a reference, we used 5 different N/P ratios of PEI/DNA polyplexes for safety 
and efficiency comparison. Our results demonstrate that calcium alginate nanoparticles 
showed comparable efficiency in comparison to all N/P ratios. MSCs transfected with 
alginate particles also show higher viability in comparison to PEI. Comparing the results 
obtained in this study, with other particles used to transfect mesenchymal stem cells 
(reviewed in table 1.1), it can be concluded that calcium alginate nanoparticles are safe 
carriers that show high expression efficiency in comparison to other non-viral vectors. 
This study confirms the safety and efficiency of calcium alginate nanoparticles as non-
viral gene carriers to human derived mesenchymal stem cells.   
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Chapter5   Future Work 
 
With the same direction of the current research, it is planned to study the efficiency of 
calcium alginate nanoparticles in vivo, carrying the therapeutic agents to tumor site, in 
various tumor models. After studying the efficiency of the transfection in vitro, it could 
be valuable to see how effective the nanoparticles could be in vivo.  
Another future perspective to the current work could be studying the nanoparticles’ 
trafficking inside the cellular domain. By labeling different cellular organelles using 
fluorescent dyes along with fluorescently tagged nanoparticles, the time frame of 
endosomal escape of the nanoparticles could be estimated. Based on the experimental 
results in chapter 3, it is hypothesized that the endosomal escape of the nanoparticles 
occurs in the time frame of 12-48 hours. How the nanoparticles travel inside the cells, 
could lead to better understanding of their mechanism as gene carriers. It is planned to 
label the nanoparticles with Lucifer yellow, the plasma DNA with YOYO-3, prior to 
transfection. To observe different cellular organelles, it is planned to label the nuclei 
with Hoescht 33342, and the endosome with LysoTracker. The escape of the plasmid 
DNA should then be visible in the endolysosome domain after 12-48 hours.  
The behavior of the nanoparticles could also be studied using various inhibiters to 
investigate the cellular uptake mechanism of the nanoparticles. Understanding of the 
cellular uptake pathway could be valuable, since higher cellular uptake could lead to 
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higher expression efficiency. The results could also be useful choosing the most 
effective size range for the nanoparticles based on the uptake pathway they go through. 
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